

May 08, 2026

Ref: NBHI/NSE-COMPL/FY2026-27/07

To,
National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra East,
Mumbai-400051

Ref: ISINs- INE995S08010, INE995S08028

Sub: Disclosure under Regulation 51(2) read with Part B, Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir/Madam,

In pursuance of Regulation 51(2) of SEBI Listing Regulations, this is to inform you that the Board of Directors ("Board") of the Company, at its meeting held today i.e. on Friday, May 08, 2026, have considered inter-alia the following:

- Based on the recommendation of the Nomination & Remuneration Committee, approved the appointment of Mr. Christopher Patrick Carroll (DIN: 11527069) as an Additional Director (in the category of Non-Executive Director), with effect from May 15, 2026, subject to the approval of the Shareholders within three (3) months from the date of appointment.
- Based on the recommendation of the Nomination & Remuneration Committee, approved the appointment of Ms. Siobhan Djihan Moynihan (DIN: 11408509) as an Additional Director (in the category of Non-Executive Director), with effect from May 15, 2026, subject to the approval of the Shareholders within three (3) months from the date of appointment.

Further, as required by the BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated June 20, 2018, we hereby confirm that Mr. Christopher and Ms. Siobhan have not been debarred from holding office of a Director by virtue of any Order passed by the SEBI or any other such authority.

- Based on the recommendation of the Nomination & Remuneration Committee, approved the elevation of Mr. Ankur Kharbanda (currently designated & serving as Executive Director and Chief Business Officer) to the position of Executive Director and Deputy Chief Executive Officer of the Company effective May 08, 2026.
- Based on the recommendation of the Nomination & Remuneration Committee, approved grant of 12,251,268 Employee stock options (ESOPs) to eligible employees under Niva Bupa Employee Stock Option Plan 2024 ('ESOP Scheme 2024').

Niva Bupa Health Insurance Company Limited

IRDAI Registration No. 145 | CIN: L66000DL2008PLC182918

Registered Office: C-98, First Floor, Lajpat Nagar, Part 1, Delhi-110024

Corporate Office: 3rd Floor, Capital Cyber scape, Golf Course Extension Road, Sector-59, Gurugram-122101, Haryana.

Website: www.nivabupa.com | Email id: investor@nivabupa.com | Tel: +91-124-6354900

- Taken on record the resignation of Ms. Penelope Ruth Dudley (DIN: 09025006) and Mr. Carlos Antonio Jaureguizar Ruiz-Jarabo (DIN: 10581062), Non-Executive Directors of the Company with effect from close of business hours on May 08, 2026, due to paucity of sufficient time to devote towards the affairs of the Company on account of their other professional commitments.

The Meeting of the Board commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M. (IST).

Kindly take the same on records.

This is for your information and records.

Thanking you,
Yours Sincerely,
For **Niva Bupa Health Insurance Company Limited**

Aparna Sharma
Company Secretary & Compliance Officer

Cc: **Axis Trustee Services Limited- Debenture Trustee**
The Ruby, 2nd Floor, SW, 29, Senapati Bapat Marg,
Dadar West, Mumbai 400 028, India